EIB backs Ethris with €30 million for broad-spectrum antiviral mRNA

Zoom in: The EIB is providing €30 million in venture debt to Ethris under the European Commission’s HERA Invest program. The financing is intended primarily to move ETH47 into the next stage of clinical development, with Phase IIb studies planned in asthma and chronic obstructive pulmonary disease (COPD).

• Ethris is also developing other respiratory mRNA programs, including ETH52 and ETH53, which target mucosal influenza vaccines and pandemic preparedness.

How it works: ETH47 is designed to activate antiviral defenses locally in the respiratory tract. The mRNA encodes interferon lambda, which is intended to trigger an innate immune response at the point where respiratory viruses enter the body. Unlike conventional antivirals, the approach does not target a specific viral protein. This could make it broadly active across different virus families and less vulnerable to viral mutations.

• The concept is based on targeting the host rather than the pathogen. By delivering mRNA encoding IFNlambda locally to the respiratory tract, ETH47 is intended to establish an antiviral state at the site of infection and inhibit viral replication.
• For Ethris, this builds on two proprietary technologies: its Stabilized Non-Immunogenic mRNA (SNIM RNA) platform and its Stabilized NanoParticle (SNaP) lipid nanoparticle technology for local delivery.

Why it matters: The company’s ambition goes beyond treating a single respiratory virus. Viral infections are major triggers of asthma and COPD exacerbations, yet current treatments for these chronic diseases do not directly address the underlying viral triggers.

What they’re saying: Ethris CEO and co-founder Carsten Rudolph said the financing would provide “further clinical proof of concept of our novel approach targeting viral threats at the point of entry.” He added that ETH47 has the potential for “broad antiviral activity against a multitude of viral families.”

• That broad activity is also what makes the program relevant to pandemic preparedness. A treatment that does not need to be redesigned for every new virus could potentially be deployed more rapidly when a new respiratory pathogen emerges.

Backstory: ETH47 is far from a new project. Ethris has been developing the candidate for several years and has already taken it through early clinical development.

• In June 2024, the company reported initial positive Phase I data for nasal administration. Full topline Phase I results, based on 40 healthy volunteers, followed in January 2025. ETH47 produced a dose-dependent increase in IFNlambda in the nasal mucosa and activated antiviral genes, while no systemic exposure was observed.
• In August 2025, the first patient was dosed in the Phase IIa trial. The study is evaluating whether ETH47 can reduce respiratory symptoms in asthma patients following rhinovirus infection. Successful completion is intended to pave the way for broader Phase IIb development.

Also notable: The EIB financing supports a development project with total costs of €91 million. The €30 million EIB contribution is structured as venture debt and is intended not only to extend Ethris’ financing runway, but also to help mobilize additional private capital.

Yes, but: That raises an obvious question: if ETH47 could potentially address a broad range of respiratory viruses, why is a public-sector lender needed to help finance it?

• The answer lies largely in the economics of pandemic preparedness. A broad-spectrum antiviral is difficult to associate with a single pathogen and therefore with a clearly defined commercial market. Its greatest value may lie precisely in being available before the next outbreak — when nobody knows which pathogen will cause it, when it will occur, or how much the product will ultimately be needed.

The big picture: The EIB itself describes this as a case of “market failure.” According to the bank, technologies addressing health threats can face limited access to appropriate commercial financing because of information asymmetries and misaligned incentives.

• HERA Invest was established to address precisely this gap. The program supports clinical-stage small and mid-sized companies developing medical countermeasures against cross-border health threats where financing needs are high but private capital may be insufficient.
• The EIB’s role is therefore not intended to replace private investors. Rather, its financing is designed to share development risk and help attract additional private capital. EIB Vice President Nicola Beer emphasized the strategic dimension, saying the financing would help strengthen “Europe’s pharmaceutical and biotechnology ecosystem, supporting health innovation, resilience and pandemic preparedness.”
• For Laurent Muschel, deputy head of DG HERA, Ethris combines several elements that are relevant to preparedness: stabilized mRNA, local nasal delivery and a mechanism that targets the host rather than the pathogen. This, he said, “may allow to fight several virus families rather than focusing on one pathogen at a time.”

What’s next: The immediate priority is clinical development. ETH47 is currently being evaluated in Phase IIa in asthma, with Phase IIb development planned in asthma and COPD. The key question will be whether the biological effect demonstrated in early studies translates into meaningful protection against virus-driven exacerbations in patients.

Beyond the news: At the same time, the Ethris financing provides another snapshot of where European pandemic preparedness stands several years after COVID-19. HERA’s remit extends beyond R&D to include procurement, stockpiling, threat assessment and securing manufacturing capacity. HERA Invest itself is designed to use public funding to mobilize private capital for medical countermeasures.

• Ethris is also receiving separate support for its preparedness activities. In early 2025, CEPI awarded the company $5 million to develop spray-dried RNA vaccines designed to improve room-temperature stability and enable mucosal administration.

Bottom line: Together, these programs reflect a broader European strategy: investing not only in vaccines against known pathogens, but also in platforms that could be adapted or deployed against emerging threats. The €30 million from the EIB is therefore more than another biotech financing deal. It is also a test of whether public risk-sharing can bring a potentially valuable but commercially uncertain antiviral technology through the clinical development gap and whether Europe can build preparedness before, rather than during, the next health emergency.